General information

There are 90 cases of breast cancer patients in our hospital from January 2017 to January 2018 were selected as the research objects. The patients were aged from 40 to 70 years old, with an average age of (51.5 ± 10.9) years old. They were randomly divided into the control group and the experimental group, with 45 cases in each group. The physical data comparison is shown in Table 1.

Table 1 Comparison of general information between the two groups ([n(%)]

Inclusion criteria

  1. 1.

    Met the diagnostic criteria for breast cancer bone metastasis;

  2. 2.

    Had complete clinical data;

  3. 3.

    The research was approved by the ethics committee of the hospital, and the patients and their family numbers knew the purpose and process of the research and signed the informed consent form.

Exclusion criteria

  1. 1.

    To combined with malignant tumor;

  2. 2.

    To eliminate physical disability;

  3. 3.

    To eliminate the patients with drug allergy.

Methods

The control group received conventional treatment with specific measures as follows:

(1) Use strontium chloride (89Sr) injection [Manufacturer: Shanghai Atomic Sinovac Pharmaceutical Co., LTD., the approval number is national medicine permission number H20041312, and the specification is 89 sr 150 MBq (4 mCi)/4 mL (bottle); 89Sr 43.6–90.4 mg/4 mL (bottle)], the dosage is 1.5–2.0 MBq (40–55 μCi)/kg.

Usage: The liquid should be injected slowly and intravenously without dilution. The injections were repeated at least 3 months;

(2) The patients should receive blood examination to ensure that the numeration of leukocyte more than 3500/mm3 and blood platelet count more than 80,000/mm3.

According to the doctor’s advice, regular blood review should be carried out for the patients. If the patient’s body has abnormal pain and other symptoms after treatment, the drug dosage can be reduced or targeted treatment can be implemented;

(3) Stop using calcium for more than 2 weeks, the use of drugs must be carried out under the guidance of professional medical personnel.

The experimental group was treated with radioactive seed 125I implantation under CT-guidance. The specific measures were as follows:

  1. 1.

    The patients were checked for various physical indicators before treatment, such as liver function, blood routine, and kidney function;

  2. 2.

    The CT (Somatom Definition AS, Equipment model: Perspective) image was imported into the Treatment Planning System(TPS) to accurately confirm the location of the lesions after scanning, and the activity, number and arrangement of particles required for treatment were calculated according to the drug dose; the diameter of radioactive seed 125I is 0.88 mm, the length is 4.5 mm, and the radiation dose of each seed is 0.4–1.0 mci (average 0.6 mci), half-life is 59.4 d, and it takes 20 d to release 94% of the radiation dose;

  3. 3.

    The patients were given local anesthesia, and the seed implantation needle was placed in the center of the lesion in the patient’s body, and parallel needle placement was conducted every 11 mm. Intermittent CT scanning was performed for the lesions, and supplement was carried out for the areas with uneven particle distribution;

  4. 4.

    Monitor the patients’ vital signs;

  5. 5.

    If there are complications in the treatment of patients should be dealt with in time.

Observation index

The indexes of CEA, CA125 and CA153 were observed in the two groups after treatment, and the pain intensity after treatment was compared between the two groups. Using Prism software to make a clear chart for each treatment index.

By comparing the therapeutic effect of the two groups of patients, the evaluation criteria were divided into 4 grades, among which grade I was reduction, fading or disappearance of bone metastasis, and no other new lesions were found; grade II was that the bone metastasis lesions had not been improved and no other new lesions were found; grade III was that bone metastases have improved and new lesions appeared; grade IV was the aggravation or deterioration of bone metastasis lesions, and new lesions appeared. According to the analysis of the treatment results by professionals, the grade I and grade II were judged as effective, grade III and grade IV were judged as invalid, and the total effective rate was the sum of grade I and grade II.

The patients were evaluated by visual analogue Scale (VAS) and told to fill in the form truthfully after treatment. The scale was divided into 10 points, in which 0 point was classified as painless, 1 to 4 was mild pain, 5 to 7 was moderate pain, and 8–10 was severe pain.

Statistical analysis treatment

The experimental data were statistically analyzed and processed by SPSS21.0 software. The count data was analyzed by x2 test and expressed by [n (%)]. The measurement data was analyzed by t-test and expressed by (x ± s). When p < 0.05, the difference has statistically significance.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Disclaimer:

This article is autogenerated using RSS feeds and has not been created or edited by OA JF.

Click here for Source link (https://www.biomedcentral.com/)